Revenue (Tables)

3 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Summary of Revenue by Sales Category

The following tables provide detail by sales category:

	Three Months Ended March 31, 2024						Three Months Ended March 31, 2023
(in millions)	U.S.		Int’l		Total		U.S.		Int’l		Total
Established Pharmaceutical Products —
Key Emerging Markets	$	—	$	928	$	928	$	—	$	912	$	912
Other	—		298		298		—		277		277
Total	—		1,226		1,226		—		1,189		1,189
Nutritionals —
Pediatric Nutritionals	514		495		1,009		459		465		924
Adult Nutritionals	364		695		1,059		353		690		1,043
Total	878		1,190		2,068		812		1,155		1,967
Diagnostics —
Core Laboratory	310		895		1,205		289		893		1,182
Molecular	42		87		129		47		100		147
Point of Care	98		41		139		93		41		134
Rapid Diagnostics	481		260		741		906		319		1,225
Total	931		1,283		2,214		1,335		1,353		2,688
Medical Devices —
Rhythm Management	271		291		562		260		267		527
Electrophysiology	269		318		587		238		267		505
Heart Failure	237		68		305		218		63		281
Vascular	254		435		689		218		399		617
Structural Heart	233		282		515		210		251		461
Neuromodulation	181		45		226		155		41		196
Diabetes Care	589		980		1,569		479		834		1,313
Total	2,034		2,419		4,453		1,778		2,122		3,900
Other	3		—		3		3		—		3
Total	$	3,846	$	6,118	$	9,964	$	3,928	$	5,819	$	9,747

Schedule of Changes in Contract Liabilities

Changes in the contract liabilities during the period are as follows:

(in millions)
Contract Liabilities:
Balance at December 31, 2023	$	545
Unearned revenue from cash received during the period	120
Revenue recognized related to contract liability balance	(116)
Balance at March 31, 2024	$	549